Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.001
Neutral
RSI(14)
47.255
Neutral
STOCH(KDJ)(9,3,3)
42.436
Neutral
ATR(14)
0.051
High Vlolatility
CCI(14)
60.520
Neutral
Williams %R
62.477
Sell
TRIX(12,20)
-0.315
Sell
StochRSI(14)
31.594
Sell
Search
Galmed Pharmaceuticals Ltd
GLMDAdd to Watchlist
0.600USD
-0.059-8.88%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
3.96MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Galmed Pharmaceuticals Ltd
Currency: USD Updated: 2026-05-15Key Insights
Galmed Pharmaceuticals Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 193 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galmed Pharmaceuticals Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Galmed Pharmaceuticals Ltd Highlights
StrengthsRisks
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.25, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 224.38K shares, increasing 25.09% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.97.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Galmed Pharmaceuticals Ltd is 6.02, ranking 292 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
4.63
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.68
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Galmed Pharmaceuticals Ltd's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Galmed Pharmaceuticals Ltd is 6.73, ranking 219 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.25, which is -44.92% below the recent high of -0.14 and -6851.57% above the recent low of -17.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 193/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Galmed Pharmaceuticals Ltd is 6.00, ranking 333 out of 382 in the Biotechnology & Medical Research industry.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Galmed Pharmaceuticals Ltd
GLMD
1
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Galmed Pharmaceuticals Ltd is 3.98, ranking 355 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.73 and the support level at 0.50, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.604
Sell
MA10
0.606
Sell
MA20
0.619
Sell
MA50
0.620
Sell
MA100
0.673
Sell
MA200
0.991
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Galmed Pharmaceuticals Ltd is 1.76, ranking 270 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.64
VaR
+9.45%
240-Day Maximum Drawdown
+79.62%
240-Day Volatility
+124.27%
Return
Best Daily Return
60 days
+26.16%
120 days
+26.16%
5 years
+290.18%
Worst Daily Return
60 days
-14.16%
120 days
-14.16%
5 years
-54.31%
Sharpe Ratio
60 days
+0.56
120 days
-0.57
5 years
-0.32
Risk Assessment
Maximum Drawdown
240 days
+79.62%
3 years
+98.70%
5 years
+99.92%
Return-to-Drawdown Ratio
240 days
-0.74
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.39
3 years
+16.86
5 years
+17.16
Volatility
Realised Volatility
240 days
+124.27%
5 years
+145.48%
Standardised True Range
240 days
+15.90%
5 years
+1153.80%
Downside Risk-Adjusted Return
120 days
-108.77%
240 days
-108.77%
Maximum Daily Upside Volatility
60 days
+213.36%
Maximum Daily Downside Volatility
60 days
+93.56%
Liquidity
Average Turnover Rate
60 days
+72.15%
120 days
+37.56%
5 years
--
Turnover Deviation
20 days
-96.97%
60 days
-32.87%
120 days
-65.05%
Peer Comparison
Biotechnology & Medical Research
Galmed Pharmaceuticals Ltd
GLMD
4.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
